Psychopharmacology

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

Adolescent cannabis use surges in Oklahoma, raising public health concerns amid rising THC potency and permissive regulations.

Read discussion of bromism, with case studies and background on bromine.

Lithium significantly reduces suicidal ideation and attempts in bipolar and major depressive disorder patients, enhancing long-term treatment outcomes.

Experts discuss the advantages of long-acting injectables in schizophrenia treatment, highlighting improved adherence, reduced relapse risk, and better patient outcomes.

Explore the complexities of treatment-resistant depression and the vital role of advanced practice providers in enhancing patient care and outcomes.

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Explore the evolving understanding of haloperidol's risks and the shift towards safer alternatives in delirium management and psychiatric care.

FDA approves Caplyta for major depressive disorder, a new sNDA for Alzheimer disease, and news in correctional psychiatry.

Discover how combining transcranial magnetic stimulation and ketamine therapy revolutionizes treatment for complex conditions like depression and pain.

American psychiatry reexamines its roots in psychopathology, challenging DSM's validity and advocating for a return to understanding mental illness.

New research reveals how Candida albicans in the gut microbiome influences alcohol consumption and aversion, offering insights for treating alcohol use disorder.

A recent study reveals that the choice of initial antipsychotic significantly impacts long-term weight gain, highlighting the complexity of treatment outcomes.

A reproductive psychiatrist discusses the implications of recent FDA announcements on medication use during pregnancy, emphasizing the importance of mental health for mothers and babies.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.

Mass shootings are often misattributed to mental illness, overshadowing the real issues of grievance, radicalization, and access to weapons.

Esketamine nasal spray shows significant improvement in emotional blunting for treatment-resistant depression, offering hope for affected patients.

A groundbreaking trial reveals ANK3 as a potential genetic predictor for liafensine's effectiveness in treating resistant depression.